These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22826617)

  • 1. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC; Wasser S; Tan T; Lim SG
    World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
    Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
    [No Abstract]   [Full Text] [Related]  

  • 5. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
    Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
    Deng H; Jiang Q; Yang Y; Zhang S; Ma Y; Xie G; Chen X; Qian Z; Wen Y; Li J; Yang J; Chen L; Zhao X; Wei Y
    Cancer Biol Ther; 2011 Feb; 11(4):401-9. PubMed ID: 21150280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
    He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D
    Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
    Zhang G; Zhang Z; Liu Z
    Tumour Biol; 2013 Jun; 34(3):1887-94. PubMed ID: 23494182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
    Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
    Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4883-4894. PubMed ID: 38165424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
    Li L; Huang K; Zhao H; Chen B; Ye Q; Yue J
    Cell Cycle; 2020 May; 19(10):1236-1252. PubMed ID: 32275843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
    Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
    Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
    Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
    Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
    World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.